Claim Details
View detailed information about this claim and its related sources.
Claim Information
Complete details about this extracted claim.
- Claim Text
-
CMS followed up by announcing in March that Medicare would reimburse older Americans prescribed Wegovy under those conditions.
- Simplified Text
-
CMS announced in March Medicare would reimburse older Americans prescribed Wegovy under those conditions
- Confidence Score
- 0.950
- Claim Maker
- CMS
- Context Type
- News Article
- Context Details
-
{ "date": "March", "drug": "Wegovy", "organization": "CMS" } - Subject Tags
- UUID
- a1165f6b-f520-4dc1-82ad-952a46b352cd
- Vector Index
- âś— No vector
- Created
- February 15, 2026 at 4:57 PM (6 months ago)
- Last Updated
- February 15, 2026 at 4:57 PM (6 months ago)
Original Sources for this Claim (1)
All source submissions that originally contained this claim.
Completed
News
21
claims
🔥
1 week ago
https://www.politico.com/newsletters/politico-pulse/2024/04/24/pharma-lobbying-up-in-2024-00153996
Pharmaceutical companies increased lobbying spending in the first quarter of 2024. Key issues driving the spending include 340B program reform, supply chain issues, and pharmacy benefit manager regulations. The article also covers Supreme Court arguments on abortion and bird flu fragments in milk.
Similar Claims (5)
Other claims identified as semantically similar to this one.
-
Simplified: One in 4 Medicare beneficiaries overweight or obese might be eligible for Wegovy coverage6 months ago
-
Simplified: FDA approved Novo Nordisk's Wegovy to reduce risk of major cardiovascular deaths in people with heart disease6 months ago
-
Simplified: Medicare is prohibited by law from covering weight-loss drugs solely for obesity6 months ago
-
Simplified: HHS and CMS intend to seek to return $4.41 billion in escrow to Medicare trust fund for needed medical care6 months ago
-
Simplified: The F.D.A. narrowed approval of Covid shots for the season that began last fall6 months ago